Nadav Kidron - 17 Apr 2023 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Role
President and CEO, Director
Signature
/s/ Nadav Kidron
Issuer symbol
ORMP
Transactions as of
17 Apr 2023
Net transactions value
$0
Form type
4
Filing time
20 Apr 2023, 06:00:24 UTC
Previous filing
16 Mar 2023
Next filing
31 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORMP Common Stock Award +279,000 +26% 1,332,098 17 Apr 2023 Direct F1
holding ORMP Common Stock 126,000 17 Apr 2023 By wholly-owned corporation
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 23,250 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.